CSL delivered a net profit after tax of $1.6 billion for H1 2023, steady at constant currency(CC). This included one-off costs associated with the acquisition of Vifor Pharma. The underlying profit was $1.82 billion, up 10% YoY and revenue was up 25% YoY at CC.

Business Highlights:

●Successful closure of Vifor acquisition: 15% revenue growth; Integration underway and cost synergies on track.

● Statutory net profit after tax (NPAT) earnings per share was $3.77.

●HEMGENIX® was approved by FDA, the first gene therapy for haemophilia B.

●Licence agreement for late-stage self-amplifying mRNA vaccine technology.

● FY23 NPATA is estimated to be in the range of $2.7 billion to $2.8 billion approximately at CC

Q: 1) Is now a good time to own CSL Limited stocks?

   2) What's your opinion or analysis of the company?